Latest & greatest articles for Alcoholic Hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Alcoholic Hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Alcoholic Hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Alcoholic Hepatitis

1. Glucocorticosteroids for people with alcoholic hepatitis. (PubMed)

Glucocorticosteroids for people with alcoholic hepatitis. Alcoholic hepatitis is a form of alcoholic liver disease characterised by steatosis, necroinflammation, fibrosis, and complications to the liver. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol. Glucocorticosteroids have been studied (...) also scanned reference lists of the studies retrieved. The last search was 18 January 2019.Randomised clinical trials assessing glucocorticosteroids versus placebo or no intervention in people with alcoholic hepatitis, irrespective of year, language of publication, or format. We considered trials with adults diagnosed with alcoholic hepatitis, which could have been established through clinical or biochemical diagnostic criteria or both. We defined alcoholic hepatitis as mild (Maddrey's score less

Full Text available with Trip Pro

2019 Cochrane

2. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review

The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

3. Dipeptidyl peptidase IV inhibitors for the treatment of non-alcoholic hepatic steatohepatitis

Dipeptidyl peptidase IV inhibitors for the treatment of non-alcoholic hepatic steatohepatitis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

4. Extra-hepatic mortality and morbidity in alcohol related liver disease

Extra-hepatic mortality and morbidity in alcohol related liver disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

5. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response (...) to treatment based on the Lille model.We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis. Our final analysis comprised 11 studies, of 2111 patients. We performed 4 meta-analyses of the effects of corticosteroids vs placebo or control, corticosteroids vs pentoxifylline, corticosteroids and pentoxifylline vs corticosteroids and placebo or control, and pentoxifylline vs placebo. In each meta-analysis, the effect of treatment on the primary outcome

2018 EvidenceUpdates

6. Two drug treatments for severe alcoholic hepatitis do not improve survival rates

Two drug treatments for severe alcoholic hepatitis do not improve survival rates Two drug treatments for severe alcoholic hepatitis do not improve survival rates Discover Portal Discover Portal Two drug treatments for severe alcoholic hepatitis do not improve survival rates Published on 23 April 2015 doi: This NIHR funded trial found that neither prednisolone nor pentoxifylline improved mortality for people with severe alcoholic hepatitis. No differences were found in mortality at 28 or 90 days (...) , or in the need for liver transplant at one year. Overall mortality was high. Nearly three in ten people died before 90 days and more than half (56%) at one year. This shows that other new treatments are needed and more needs to be done to encourage complete abstinence from alcohol following severe alcoholic hepatitis. Share your views on the research. Why was this study needed? UK estimates from 2009 show a quarter of adults drink in a hazardous or harmful way. People with prolonged and heavy alcohol use can

2018 NIHR Dissemination Centre

7. Can we reliably predict response to corticosteroid treatment in severe alcoholic hepatitis? (PubMed)

Can we reliably predict response to corticosteroid treatment in severe alcoholic hepatitis? 29881814 2018 11 14 2471-254X 2 6 2018 Jun Hepatology communications Hepatol Commun Can we reliably predict response to corticosteroid treatment in severe alcoholic hepatitis? 625-627 10.1002/hep4.1191 Chokshi Shilpa S Chief Scientific Officer Institute of Hepatology Foundation for Liver Research London United Kingdom. eng Editorial 2018 04 27 United States Hepatol Commun 101695860 2471-254X 2018 03 29

Full Text available with Trip Pro

2018 Hepatology communications

8. Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome (PubMed)

Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome Severe alcoholic hepatitis (SAH) has a high mortality rate, and corticosteroid therapy is effective in 60% patients. This study aimed to investigate a baseline metabolic phenotype that could help stratify patients not likely to respond to steroid therapy and to have an unfavorable outcome. Baseline urine metabolome was studied in patients with SAH using ultra-high performance liquid

Full Text available with Trip Pro

2018 Hepatology communications

9. Two drug treatments for severe alcoholic hepatitis do not improve survival rates

Two drug treatments for severe alcoholic hepatitis do not improve survival rates Two drug treatments for severe alcoholic hepatitis do not improve survival rates Discover Portal Discover Portal Two drug treatments for severe alcoholic hepatitis do not improve survival rates Published on 23 April 2015 doi: This NIHR funded trial found that neither prednisolone nor pentoxifylline improved mortality for people with severe alcoholic hepatitis. No differences were found in mortality at 28 or 90 days (...) , or in the need for liver transplant at one year. Overall mortality was high. Nearly three in ten people died before 90 days and more than half (56%) at one year. This shows that other new treatments are needed and more needs to be done to encourage complete abstinence from alcohol following severe alcoholic hepatitis. Share your views on the research. Why was this study needed? UK estimates from 2009 show a quarter of adults drink in a hazardous or harmful way. People with prolonged and heavy alcohol use can

2018 NIHR Dissemination Centre

10. Alcoholic Hepatitis: Lost in Translation (PubMed)

Alcoholic Hepatitis: Lost in Translation Alcoholic hepatitis is the most severe and acute form of alcoholic liver disease. The mortality rate associated with alcoholic hepatitis is high, largely due to the lack of suitable pharmacological interventions. While there has been substantial research in the area, generating pharmacological interventions has been plagued by the lack of a robust mouse model both for testing and for understanding the underlying pathology. A number of major notable (...) advances have been made in this area recently, with the goal of generating a mouse model of alcoholic hepatitis. The purpose of this article is to review recent advances in modeling alcoholic liver disease both in vitro and in vivo in the mouse, and place them in the context of the greater spectrum of alcoholic liver disease, with a focus on how we can translate current advances into a high-fidelity model of alcoholic hepatitis. In addition, we will review the basic mechanisms of alcoholic hepatitis

Full Text available with Trip Pro

2017 Journal of clinical and translational hepatology

11. Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy (PubMed)

Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy The clinical presentation of alcoholic hepatitis (AH) can be mimicked by other alcoholic liver diseases. The aim of this study was to identify clinical features that predict AH on liver biopsy. Biopsies from patients hospitalized for presumed severe AH were used to identify a derivation cohort (101 patients) and validation cohort (71 patients). Using histologic scores for hepatocyte (...) characteristic curve of 0.72. Conclusion: The combination of an elevated leukocyte count and a nodular liver surface in the absence of active infection retrospectively identified patients with a high likelihood of histologic AH for whom liver biopsy may not be necessary. For patients with suspected severe AH who do not fulfill these criteria, liver biopsy is important to exclude other variants of alcoholic liver disease. (Hepatology Communications 2017;1:1070-1084).

Full Text available with Trip Pro

2017 Hepatology communications

12. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. (PubMed)

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage (...) to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot

Full Text available with Trip Pro

2017 Lancet

13. Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease (PubMed)

Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease The aim of this study was to investigate the role of osteopontin (OPN) in hematopoietic stem cell (HPSC) mobilization to the liver and its contribution to alcoholic liver disease (ALD). We analyzed young (14-16 weeks) and old (>1.5 years) wild-type (WT) littermates and global Opn knockout (Opn-/- ) mice for HPSC mobilization to the liver. In addition (...) to old Opn-/- mice. Granulocyte colony-stimulating factor and macrophage colony-stimulating factor were increased in Opn-/- mice, suggesting potential migration of HPSCs from the BM to the liver. Furthermore, ethanol-fed Opn-/- mice showed significant hepatic PMN infiltration and hemosiderin compared to WT mice. As a result, ethanol feeding caused greater liver injury in Opn-/- compared to WT mice. Conclusion: Opn deletion promotes HPSC mobilization, PMN infiltration, and iron deposits in the liver

Full Text available with Trip Pro

2017 Hepatology communications

14. Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis (PubMed)

Interaction between the patatin‐like phospholipase domain‐containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis Only a subset of subjects with excessive alcohol consumption develops alcoholic liver disease (ALD). One of the major risk factors for ALD is the genetic variant of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene. Coffee is one of the most commonly consumed beverages, and coffee consumption has been associated (...) with lower levels of serum alanine aminotransferase. The aim of this study was to investigate the role of coffee drinking and PNPLA3 rs738409 and their association with alcoholic hepatitis (AH) in a well-characterized cohort of subjects from the Translational Research and Evolving Alcoholic Hepatitis Treatment consortium. AH subjects and heavy drinking controls without a history of liver disease who were enrolled between May 2013 and May 2016 were included (n = 339), and the details of alcohol and coffee

Full Text available with Trip Pro

2017 Hepatology communications

15. Glucocorticosteroids for people with alcoholic hepatitis. (PubMed)

Glucocorticosteroids for people with alcoholic hepatitis. Alcoholic hepatitis is a form of alcoholic liver disease, characterised by steatosis, necroinflammation, fibrosis, and potential complications to the liver disease. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol. Glucocorticosteroids (...) are used as anti-inflammatory drugs for people with alcoholic hepatitis. Glucocorticosteroids have been studied extensively in randomised clinical trials in order to assess their benefits and harms. However, the results have been contradictory.To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.We identified trials through electronic searches in Cochrane Hepato-Biliary's (CHB) Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, and Science Citation

Full Text available with Trip Pro

2017 Cochrane

16. Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase (PubMed)

Severe Alcoholic Hepatitis: Atypical Presentation with Markedly Elevated Alkaline Phosphatase Alcoholic hepatitis (AH) is an acute inflammatory liver disease with poor prognosis. Infections in AH are difficult to detect and contribute to short-term mortality. Intrahepatic cholestasis and elevated alkaline phosphatase levels are also associated with worse outcomes. This report describes an uncommon presentation of severe AH.

Full Text available with Trip Pro

2017 Journal of clinical and translational hepatology

17. Role of gp91phox in hepatic macrophage programming and alcoholic liver disease (PubMed)

Role of gp91phox in hepatic macrophage programming and alcoholic liver disease Hepatic macrophages (MΦs) are important in the development and progression of alcoholic liver disease (ALD). This study investigates the role of gp91phox (nicotinamide adenine dinucleotide phosphate oxidase 2) in the severity of ALD and specifically in regulating hepatic MΦ efferocytic capability and the subsequent reprogramming associated with resolution of inflammation. After 4 weeks of ethanol feeding, more severe (...) ALD developed in gp91phox-/- mice than in wild-type (WT) C57Bl/6J mice, evidenced by increased liver injury and inflammation. This phenomenon was not sex dependent, and thus the majority of experiments were performed with female mice. While total hepatic MΦ numbers did not differ between genotypes, hepatic infiltrating MΦs (IMs) were slightly more numerous in gp91phox-/- mice, and both IMs and resident Kupffer cells displayed enhanced proinflammatory and reduced tissue-restorative programming

Full Text available with Trip Pro

2017 Hepatology communications

18. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA Infections are common in patients with severe alcoholic hepatitis (SAH), but little information is available on how to predict their development or their effects on patients. Prednisolone is advocated for treatment of SAH, but can increase susceptibility to infection. We compared the effects of infection

Full Text available with Trip Pro

2017 EvidenceUpdates

19. Is pentoxifylline effective in alcoholic hepatitis? –First update. (PubMed)

Is pentoxifylline effective in alcoholic hepatitis? –First update. This article updates the June 2014 Living FRISBEE (Living FRISBEE: Living FRIendly Summary of the Body of Evidence using Epistemonikos). It incorporates a new systematic review identifying one study not included in previous reviews. The new evidence leads to substantial changes in the existing evidence.Pentoxifylline is an inhibitor of tumor necrosis factor, and has been proposed as treatment for alcoholic hepatitis. However (...) , it is not clear if it is effective, or if it adds benefit to the treatment with corticosteroids. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified three systematic reviews including eight randomized controlled trials addressing the question of this article. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded pentoxifylline probably leads to little or no difference in mortality in alcoholic

Full Text available with Trip Pro

2016 Medwave

20. Current Management of Alcoholic Hepatitis and Future Therapies (PubMed)

Current Management of Alcoholic Hepatitis and Future Therapies Alcohol is one of the most common etiologies of liver disease, and alcoholic liver disease overall is the second most common indication for liver transplantation in the United States. It encompasses a spectrum of disease, including fatty liver disease, alcoholic hepatitis (AH), and alcoholic cirrhosis. AH can range from mild to severe disease, with severe disease being defined as: Discriminant Function (DF) ≥ 32, or Model for End (...) -stage Liver Disease (MELD) ≥ 21, or presence of hepatic encephalopathy. Management of the mild disease consists mainly of abstinence and supportive care. Severe AH is associated with significant mortality. Currently, there is no ideal medical treatment for this condition. Besides alcohol cessation, corticosteroids have been used with conflicting results and are associated with an inherent risk of infection. Overall steroids have shown short term benefit when compared to placebo, but they have

Full Text available with Trip Pro

2016 Journal of clinical and translational hepatology